Fenofibrate



Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Fenofibrate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FEALTY AZARD INSTRUMENT

SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877–715–9305 Outside the US & Canada: +800 2436 2255 (1–800-CHEMCALL) or call +613 9573 3112

SYNONYMS

C20-H21-Cl-O4, ClC6H4C(=O)C6H4OC(CH3)2CO2CH(CH3)2, "propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, ", "1-methylethyl ester", "2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester", "isopropyl [4' -(p-chlorobenzoyl)phenoxy]-2-phenoxy-2-methylpropionate", "isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionate", LF-178, Lipanthyl, Lipanthyl, Lipidax, Lipifen, Lipoclar, Lipofene, Liposit, Lipovas, Lipsin, Normalip, Protocetofen, Procetoken, Scleril, Secalip, Sigurtil, Tilene, Volutine, "antihyperlipoproteinemic/ antihyperlipoproteinaemic", "lipid regulating agent"





EMERGENCY OVERVIEW

RISK

May cause SENSITISATION by skin contact. Harmful by inhalation, in contact with skin and if swallowed.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.

Chlorphenoxy compounds irritate the digestive system and cause nausea and vomiting, chest pain, and diarrhea.

Taking large doses can result in mineral imbalance, temperature changes, hyperventilation, low blood pressure, dilated blood vessels, damage to the heart and liver with death of white blood cells, and convulsions.

■ Side-effects of clofibrate intake include nausea, gastrointestinal discomfort (with diarrhoea), drowsiness, headache, dizziness, weight-gain, pruritus, skin rash, alopecia, leucopenia, pancreatitis and cardiac arrhythmias.

A rise in serum aminotransferase values may also occur following clofibrate treatment; hepatomegaly (enlarged liver) has been reported though this seems not to be associated with hepatotoxicity.

EYE

There is some evidence to suggest that this material can causeeye irritation and damage in some persons.

Corneal injury resulting from 2,4-D exposure may be slow to heal.

SKIN

Skin contact with the material may be harmful; systemic effects may resultfollowing absorption.

The material is not thought to be a skin irritant (as classified using animal models).

Abrasive damage however, may result from prolonged exposures.

Open cuts, abraded or irritated skin should not be exposed to this material.

■ 2,4-D and its derivatives can all be absorbed through the skin of humans.

Severe peripheral neuropathy has followed causing limb paralysis and loss of sensation.

Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects.

Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED

The material is not thought to produce respiratory irritation (as classified using animal models).

Nevertheless inhalation of dusts, or fume, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress. Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

Inhalation of chlorophenoxy dusts or mists may result in sore throat, burning sensations in the throat and chest, cough, tears, inflamed nose, dizziness and inco-ordination, as a result of absorption from the lungs.

CHRONIC HEALTH EFFECTS

There has been concern that this material can cause cancer or mutations, but there is not enough data to make an assessment.

Skin contact with the material is more likely to cause a sensitization reaction in some persons compared to the general population.

Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

There is some evidence that human exposure to the material may result in developmental toxicity. This evidence is based on animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects.

Clofibrate was tested carcinogenicity by oral administration in the diet of rats and mice. In rats clofibrate produced hepatocellular carcinomas.

Clofibrate was tested in several experiments by combined administration with other chemicals. It enhanced the hepatocarcinogenicity of N-nitrosamines in rats and hamsters. It did not enhance the carcinogenicity of 2-acetylaminofluorene in rat liver.

Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung.

Chlorophenoxy herbicides cause an increased risk of cancers of soft tissue, lymph and bronchi. Inflammation of skin can result from long term contact.

Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis).

	Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS				
NAME		CAS RN	%		
fenofibrate		49562-28-9	>98		

Section 4 - FIRST AID MEASURES

SWALLOWED

 \cdot IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. \cdot Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

EYE

■ If this product comes in contact with the eyes: · Wash out immediately with fresh running water. · Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

SKIN

■ If skin contact occurs: · Immediately remove all contaminated clothing, including footwear · Flush skin and hair with running water (and soap if available).

INHALED

· If fumes or combustion products are inhaled remove from contaminated area. · Lay patient down. Keep warm and rested.

NOTES TO PHYSICIAN

Treat symptomatically.

Following exposures to chlorphenoxy compounds:

• Acute toxic reactions are rare. The by-product of production, dioxin, may be implicated in subacute features such as hepatic enlargement, chloracne, neuromuscular symptoms and deranged porphyrin metabolism.

Large intentional overdoses result in coma, metabolic acidosis, myalgias, muscle weakness, elevated serum creatine kinase, myoglobinuria, irritation of the skin, eyes, respiratory tract and gut and mild renal and hepatic dysfunction.

Section 5 - FIRE FIGHTING MEASURES					
Vapour Pressure (mmHG):	Negligible				
Upper Explosive Limit (%):	Not available.				
Specific Gravity (water=1):	80-81				
Lower Explosive Limit (%):	Not available				

EXTINGUISHING MEDIA

· Foam.

· Dry chemical powder.

FIRE FIGHTING

· Alert Emergency Responders and tell them location and nature of hazard.

· Wear breathing apparatus plus protective gloves.

GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS

· Combustible solid which burns but propagates flame with difficulty.

• Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen chloride, phosgene, other pyrolysis products typical of burning organic material.

May emit poisonous fumes.

May emit corrosive fumes.

FIRE INCOMPATIBILITY

Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

PERSONAL PROTECTION

Glasses: Chemical goggles. Gloves: Respirator: Particulate

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS

- \cdot Clean up waste regularly and abnormal spills immediately.
- · Avoid breathing dust and contact with skin and eyes.
- · Wear protective clothing, gloves, safety glasses and dust respirator.
- · Use dry clean up procedures and avoid generating dust.
- · Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- · Dampen with water to prevent dusting before sweeping.
- · Place in suitable containers for disposal.

MAJOR SPILLS

Moderate hazard.

- · CAUTION: Advise personnel in area.
- · Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

· Avoid all personal contact, including inhalation.

· Wear protective clothing when risk of exposure occurs.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.

· Do NOT cut, drill, grind or weld such containers.

In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS

Glass container.

- · Polyethylene or polypropylene container.
- · Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS

- · Store in original containers.
- · Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS

The following materials had no OELs on our records • fenofibrate: CAS:49562-28-9

PERSONAL PROTECTION



RESPIRATOR

Particulate

Consult your EHS staff for recommendations

EYE

■ When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

· Chemical goggles

· Face shield. Full face shield may be required for supplementary but never for primary protection of eyes

• Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET

■ NOTE: The material may produce skin sensitization in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:

- · frequency and duration of contact,
- · chemical resistance of glove material,
- · glove thickness and
- · dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).

• When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.

• When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.

· Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

· Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.

- · Double gloving should be considered.
- · PVC gloves.
- · Protective shoe covers.
- · Head covering.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.

- · polychloroprene
- · nitrile rubber
- \cdot butyl rubber
- · fluorocaoutchouc
- \cdot polyvinyl chloride

Gloves should be examined for wear and/ or degradation constantly.

OTHER

· For quantities up to 500 grams a laboratory coat may be suitable.

• For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.

- · For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- · For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- · Eye wash unit.
- · Ensure there is ready access to an emergency shower.
- · For Emergencies: Vinyl suit.

ENGINEERING CONTROLS

Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES

Solid. Does not mix with water. Sinks in water.			
State	Divided solid	Molecular Weight	360.86
Melting Range (°F)	Not available	Viscosity	Not available
Boiling Range (°F)	Not available	Solubility in water (g/L)	Partly miscible
Flash Point (°F)	>230	pH (1% solution)	Not applicable
Decomposition Temp (°F)	Not available.	pH (as supplied)	Not applicable
Autoignition Temp (°F)	Not available	Vapour Pressure (mmHG)	Negligible
Upper Explosive Limit (%)	Not available.	Specific Gravity (water=1)	80-81
Lower Explosive Limit (%)	Not available	Relative Vapor Density (air=1)	>1
Volatile Component (%vol)	Negligible	Evaporation Rate	Not applicable

APPEARANCE

Clear colourless to pale yellow liquid with characteristic faintly acrid odour and a taste acrid at first becoming sweet; does not mix well with water. Miscible in alcohol, acetone, chloroform, ether, hexane.

Section 10 - CHEMICAL STABILITY

CONDITIONS CONTRIBUTING TO INSTABILITY

- \cdot Presence of incompatible materials.
- · Product is considered stable.

STORAGE INCOMPATIBILITY

Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION

fenofibrate

TOXICITY AND IRRITATION

FENOFIBRATE:

unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

TOXICITY IRRITATION

Oral (rat) LD50: >2000 mg/kg Nil Reported

Oral (mouse) LD50: 1600 mg/kg

Oral (dog) LD50: >4000 mg/kg

Oral (hamster) LD50: >5000 mg/kg

■ Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's edema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type.

Fibrates are a class of amphiphilic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolaemia (high cholesterol), and are therefore hypolipidaemic agents.

Fibrates are agonists of the PPAR-a receptor in muscle, liver, and other tissues. Activation of PPAR-a signaling results in:

· Increased beta-oxidation in the liver

 \cdot Decreased hepatic triglyceride secretion

· Increased lipoprotein lipase activity, and thus increased VLDL (Very Low Density Lipoprotein) clearance

- · Increased HDL (High Density Lipoprotein)
- · Increased clearance of remnant particles

· Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Since fibrates increase the cholesterol content of bile, they increase the risk for gallstones.

In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to renal failure. A powerful statin drug, cerivastatin (Lipobay), was withdrawn because of this complication. The less lipophilic statins are less prone to cause this reaction, and are probably safer when combined with fibrates.

Fibrates are structurally and pharmacologically related to the thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more specifically PPARy.

Adverse clinical effects have been reported for 7% of the exposures to thiazolidinediones, the most frequent of which were hypoglycemia (2%), hyperglycaemia (1%), and drowsiness (1%).

Oedema is an adverse event associated with thiazolidinedione therapy. The potential for mild-to-moderate peripheral oedema with thiazolidinedione is known, especially in patients who have heart failure or use insulin.

Vary rarely, reports of new onset or worsening (diabetic) macular oedema with decreased visual acuity have been reported with the use of thiazolidinediones.

Subcutaneous benign adipose tissue tumours (lipomas) have been observed in rats treated with thiazolidinedione drugs, and are probably related to the pharmacodynamic activity of this drug class. Urinary bladder tumours were probably secondary to formation of urinary calculi, and are unlikely to pose a carcinogenic risk in humans.

Changes in liver weight, normocytic anaemia, changes in platelet count, diarrhoea, maternal and paternal effects, effects on newborn, specific developmental abnormalities (musculoskeletal system, urogenital system), effects on fertility recorded.

Section 12 - ECOLOGICAL INFORMATION

No data

Ecotoxicity

Ingredient fenofibrate

Persistence: Water/Soil	Persistence: Air
HIGH	

Bioaccumulation LOW

Mobility MED

Section 13 - DISPOSAL CONSIDERATIONS

US EPA Waste Number & Descriptions

B. Component Waste Numbers

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue,

use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste number F027

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue,

use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste number F027

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste number F027

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue,

use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste number F027

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste number F027

When fenofibrate is present as a solid waste as a discarded commercial chemical product, off-specification species, as a container residue, or a spill residue, use EPA waste number U240 (waste code T).

For discarded unused formulations containing fenofibrate use hazardous waste

number F027

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

Puncture containers to prevent re-use and bury at an authorized landfill.

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- · Reuse

Recycling

· Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

· Recycle wherever possible.

· Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

No data for fenofibrate (CAS: , 49562-28-9)

Section 16 - OTHER INFORMATION

ND

Substance CAS Suggested codes fenofibrate 49562-28-9

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

■ The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Nov-15-2009 Print Date:Feb-12-2011